A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer
Completed
- Conditions
- Lung Cancer
- Registration Number
- NCT03047616
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Brief Summary
Several immune checkpoint inhibitors targeting the PD-1 pathway have been developed with clinical trials showing an approximately 20% durable response in unselected patients with advanced non-small cell lung cancer (NSCLC). At the moment, no clear biomarker exists to accurately predict anti-PD1/PDL1 tumor responsiveness. The goal of this study is to broadly discover and evaluate the utility of blood based biomarkers for use in measuring and predicting response to immunotherapy in patients with lung cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 88
Inclusion Criteria
- Advanced Metastatic NSCLC
- Scheduled to initiate an immune checkpoint inhibitor
- Age >= 18 years
- Able to provide informed consent
Exclusion Criteria
- Other, unrelated, concomitant active, invasive malignancy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the correlation between markers identified in the blood and in the primary tumor. 5 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Abramson Cancer Center of the University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States